A CDK4 amplification test looks for extra copies of the CDK4 gene in tumor cells. In soft-tissue pathology, this finding is most closely associated with atypical lipomatous tumor/well-differentiated liposarcoma and dedifferentiated liposarcoma, which often contain high-level amplification across chromosome 12q13-15 that includes both CDK4 and MDM2. CDK4 amplification can support tumor classification, but it is usually interpreted with MDM2 testing, microscopic appearance, tumor location, imaging, and clinical context. It is not a blood test for cancer risk and it does not mean that CDK4 was inherited. The result is typically a somatic copy-number alteration present in the tumor. A positive result may also have research or treatment relevance because CDK4 is a cell-cycle target, although current treatment decisions are not based on amplification alone. A negative result requires caution because MDM2 is the more central diagnostic marker and some genuine liposarcomas do not show clearly detectable CDK4 amplification.
- CDK4 amplification means the tumor has extra copies of CDK4, usually as part of a broader 12q13-15 amplicon rather than a hereditary gene change.
- The strongest diagnostic use is in well-differentiated and dedifferentiated liposarcoma, especially when morphology overlaps with benign fat tumors or other sarcomas.
- MDM2 testing is usually more central than CDK4 alone: the two genes are frequently co-amplified, but MDM2 amplification is the defining molecular hallmark in most cases.
- A negative CDK4 result does not exclude liposarcoma: testing method, tumor content, and MDM2 status must be reviewed.
- No fasting is required: testing is usually performed on biopsy or surgical tumor tissue using FISH, PCR, chromosomal microarray, or next-generation sequencing.
Table of Contents
- What CDK4 amplification means
- Role in liposarcoma diagnosis
- When the test is ordered
- How CDK4 amplification is tested
- How to interpret positive and negative results
- Prognosis and treatment relevance
- Limitations and next steps
What CDK4 amplification means
CDK4 is a gene that encodes cyclin-dependent kinase 4, a protein that helps cells move from the G1 phase into the S phase of the cell cycle. In normal cells, CDK4 activity is tightly controlled. When a cancer cell carries many extra copies of CDK4, the resulting overactivity can promote continued cell division.
In well-differentiated and dedifferentiated liposarcoma, CDK4 is commonly amplified together with MDM2 on chromosome 12q13-15. These amplified segments may appear in ring chromosomes or giant marker chromosomes. MDM2 suppresses p53 signaling, while CDK4 drives cell-cycle progression, giving the tumor two complementary growth advantages.
The word amplification is more specific than a simple copy-number gain. In molecular oncology, amplification generally implies a high-level increase beyond the normal two gene copies. Laboratories use different technical thresholds depending on the assay. FISH may compare CDK4 signals with a chromosome control probe, while next-generation sequencing estimates copy number from sequencing depth and tumor purity.
Because thresholds differ, the exact numerical copy number should be interpreted according to the laboratory’s validated method rather than against one universal cutoff.
CDK4 amplification is a somatic tumor marker in this setting. It is not the same as an inherited CDK4 pathogenic variant associated with rare familial melanoma susceptibility. A liposarcoma amplification result does not by itself create a hereditary cancer concern for relatives.
Role in liposarcoma diagnosis
CDK4 amplification is most useful as an adjunct to pathology when distinguishing atypical lipomatous tumor/well-differentiated liposarcoma from benign fatty tumors, or dedifferentiated liposarcoma from other high-grade sarcomas.
Atypical lipomatous tumor and well-differentiated liposarcoma are the same tumor type biologically. The terminology often reflects location and surgical behavior. A resectable tumor in an extremity may be called atypical lipomatous tumor, while a deeply located retroperitoneal lesion is often called well-differentiated liposarcoma because complete excision is harder and repeated local recurrence can be a major problem.
These tumors can look deceptively similar to lipoma, particularly on small biopsies. Molecular evidence of MDM2 amplification, often accompanied by CDK4 amplification, strongly supports ALT/WDLPS.
Dedifferentiated liposarcoma contains a non-lipogenic sarcoma component arising in association with ALT/WDLPS. The high-grade area can resemble undifferentiated pleomorphic sarcoma, spindle-cell sarcoma, myxofibrosarcoma, or other malignancies. Demonstrating amplification of the 12q13-15 region can reveal the underlying liposarcoma lineage even when the sampled tissue contains little obvious fat.
The related MDM2 amplification test for liposarcoma is usually the key molecular test in this differential. CDK4 adds supportive information and can be especially useful when immunohistochemistry and morphology are equivocal.
CDK4 amplification should not be confused with the DDIT3 fusion test for myxoid liposarcoma. Myxoid liposarcoma is a different molecular subtype characterized by FUS::DDIT3 or, less often, EWSR1::DDIT3 rather than MDM2/CDK4 amplification.
When the test is ordered
A pathologist may request CDK4 testing when the microscopic appearance and clinical setting raise the possibility of ALT/WDLPS or DDLPS but the diagnosis is not fully secure.
Common situations include:
- a large deep-seated fatty tumor with thick septa or atypical cells;
- a retroperitoneal sarcoma in which dedifferentiated liposarcoma is a major diagnostic possibility;
- a recurrent lipomatous tumor that was previously called a lipoma;
- a high-grade spindle-cell or pleomorphic sarcoma adjacent to fat;
- discordant MDM2 immunohistochemistry and morphology; or
- a broad tumor sequencing panel that unexpectedly reports CDK4 and MDM2 co-amplification.
Not every ordinary lipoma needs molecular testing. Clinical and radiologic features can identify many benign lesions, and overt ALT/WDLPS may be diagnosable morphologically. Molecular testing is most valuable in borderline cases or when the classification would change surgery, follow-up, or systemic-treatment discussions.
Location matters. Retroperitoneal masses require particular care because dedifferentiated liposarcoma is common in that site and can be morphologically diverse. Expert sarcoma pathology review is often worthwhile before a difficult tumor is labeled as an unclassified sarcoma.
How CDK4 amplification is tested
Testing usually uses formalin-fixed, paraffin-embedded tissue from a core biopsy or resection. A pathologist selects an area with viable tumor and sufficient tumor cells.
Fluorescence in situ hybridization (FISH) uses fluorescent probes that bind the CDK4 region and, often, a chromosome control. The pathologist counts signals in tumor-cell nuclei and assesses whether the ratio or absolute signal pattern meets the laboratory’s amplification criteria.
Quantitative PCR can estimate gene copy number, although it provides less spatial information than FISH.
Chromosomal microarray can show amplification across the 12q region and reveal the broader copy-number pattern.
Next-generation sequencing panels can infer CDK4 amplification and simultaneously evaluate MDM2 and other genes. Accuracy depends on tumor purity, assay design, sequencing depth, and bioinformatic normalization.
Immunohistochemistry for CDK4 protein is related but not identical. Positive staining can support the diagnosis, yet protein expression does not prove gene amplification. MDM2 and CDK4 immunostains are commonly used as screening adjuncts, with molecular confirmation when the result will be decisive.
No fasting, sedation, or medication changes are needed specifically for the molecular test. Any preparation relates to how the biopsy or surgery is performed, not to CDK4 analysis itself.
How to interpret positive and negative results
A positive CDK4 amplification result means the tested tumor contains an abnormally high number of CDK4 copies. In a compatible adipocytic or retroperitoneal tumor, especially with MDM2 co-amplification, this strongly supports ALT/WDLPS or DDLPS.
| Finding | Most useful interpretation | Important caution |
|---|---|---|
| CDK4 and MDM2 both amplified | Strongly supports ALT/WDLPS or DDLPS in the correct morphologic setting | Final classification still depends on histology and tumor site |
| CDK4 amplified, MDM2 not amplified | Unusual pattern that deserves technical and diagnostic review | CDK4 alone is less specific for WDLPS/DDLPS |
| MDM2 amplified, CDK4 not amplified | Can still support WDLPS/DDLPS | Not every tumor co-amplifies CDK4 |
| Neither amplified | Makes classic ALT/WDLPS or DDLPS less likely | Sampling, assay sensitivity, and rare exceptions must be considered |
A negative CDK4 test should never be used alone to overturn convincing MDM2-positive pathology. MDM2 is more consistently amplified and generally has greater diagnostic centrality.
The report may also give a copy number or ratio. There is no universal “normal range” comparable with a blood chemistry test. The laboratory’s own validated cutoff defines amplification.
Prognosis and treatment relevance
CDK4 amplification is biologically important, but the presence of amplification alone does not determine stage or prognosis. The most important clinical distinctions remain tumor subtype, location, completeness of surgery, grade of dedifferentiation, recurrence pattern, and metastatic disease.
ALT/WDLPS does not metastasize unless dedifferentiation occurs, but deep tumors—especially in the retroperitoneum—can recur repeatedly and cause serious local problems. DDLPS has a greater risk of metastasis and disease-related death.
Some older studies suggested that higher CDK4 amplification levels may correlate with recurrence in abdominal WDLPS. These observations are not used as a universal quantitative risk threshold in current routine practice.
Because CDK4 is a druggable kinase, CDK4/6 inhibitors have been studied in advanced WDLPS/DDLPS. Palbociclib showed disease-control activity in phase II studies, and additional CDK4-directed strategies continue to be investigated. However, CDK4 amplification is so common in this tumor type that it functions more as a biological hallmark than as a simple companion diagnostic that guarantees response.
Modern DDLPS drug development also targets MDM2, cell-cycle dependencies, and combinations intended to overcome resistance. A 2024 multidisciplinary position statement emphasized the importance of expert pathology and molecular diagnosis while noting the continuing need for more effective systemic therapies.
Patients should therefore not interpret “CDK4 amplified” as meaning that a CDK4 inhibitor is automatically indicated. Treatment is selected by a sarcoma specialist based on disease setting, prior therapy, resectability, symptoms, and available evidence or clinical trials.
Limitations and next steps
The main limitation is specificity. CDK4 amplification can occur in tumors outside WDLPS/DDLPS, so the result must be anchored to morphology and location. MDM2 and CDK4 protein expression can also occur without true amplification.
Sampling is another issue. A large dedifferentiated liposarcoma can contain different components, and a core biopsy samples only a small region. The molecular amplicon is generally shared, but the biopsy may not show the lipogenic component needed for confident morphologic recognition.
Technical factors such as low tumor content, necrosis, fixation damage, and unusual chromosome structure can complicate copy-number analysis. If a result conflicts with the pathology, options include repeating FISH, testing MDM2, reviewing another tissue block, or obtaining expert sarcoma-pathology consultation.
After a positive result, the practical next step is not hereditary testing. Instead, clinicians should confirm the final pathologic classification and integrate imaging and surgical findings. After a negative result in a highly suspicious tumor, MDM2 testing and diagnostic review are more useful than assuming the lesion is benign.
For patients, the most useful question is: Does this amplification clarify what type of tumor I have, and does that classification change treatment or follow-up? That is the clinical purpose of the test.
CDK4 amplification is a DNA finding, not just protein staining
CDK4 amplification means that tumor cells contain increased copies of the CDK4 genomic region. This is different from simply showing that CDK4 protein is present by immunohistochemistry. Protein expression can support a diagnosis in the right setting, but staining intensity is not a direct measurement of gene copy number and can overlap with other tumors. FISH, chromosomal microarray methods, and appropriately validated next-generation sequencing approaches can assess copy-number gain more directly.
In well-differentiated and dedifferentiated liposarcoma, CDK4 amplification commonly occurs as part of the characteristic 12q13-15 amplicon and is frequently accompanied by MDM2 amplification. MDM2 is generally the more central diagnostic marker, especially when distinguishing atypical lipomatous tumor/well-differentiated liposarcoma from benign lipoma. CDK4 adds supporting molecular context, particularly when morphology, anatomic site, and other findings are concordant. A tumor should not be labeled liposarcoma solely because CDK4 copy number is increased.
Sampling matters in dedifferentiated liposarcoma
Dedifferentiated liposarcoma can be heterogeneous. One area may retain recognizable well-differentiated fatty tumor while another looks like a nonlipogenic high-grade sarcoma. A small core biopsy may sample only one component. Imaging and gross-pathology correlation can therefore be important when selecting tissue for molecular testing. If a retroperitoneal mass has a fatty component and a solid component, the solid area may be particularly important to sample when dedifferentiation is suspected.
This heterogeneity also explains why molecular results must be reconciled with pathology rather than read in isolation. A convincing MDM2/CDK4 amplification pattern in a morphologically ambiguous sarcoma can support the diagnosis, while a negative result in a tiny or low-tumor sample may warrant repeat testing on a better block. Conversely, amplification in a tumor from an unusual site requires careful clinicopathologic review because other neoplasms can occasionally show changes in the same chromosomal region.
What the result does and does not predict
For most patients, CDK4 amplification is primarily a classification biomarker. It does not provide a simple numerical forecast of recurrence or survival. Prognosis in liposarcoma is driven by factors such as tumor subtype, anatomic site, resectability, completeness of surgery, dedifferentiation, grade, size, and metastatic disease. The molecular finding should be integrated with those factors.
CDK4 is also a biologically attractive treatment target, and CDK4/6 inhibitors have been studied in well-differentiated and dedifferentiated liposarcoma. However, amplification alone does not guarantee sensitivity to a CDK4-directed drug, and a molecular report should not be read as an automatic treatment recommendation. Treatment choices depend on disease setting, prior therapy, available evidence, regulatory status, and clinical-trial options.
CDK4 amplification is not generally used as a blood-based surveillance marker after treatment. Follow-up is usually based on the sarcoma subtype, imaging, examination, symptoms, and the treatment plan. If recurrence is suspected, the original molecular profile may help confirm that a new lesion is related, but repeat biopsy decisions are individualized.
Location changes how the diagnosis is named and managed
An atypical lipomatous tumor and a well-differentiated liposarcoma share the same core biology, including frequent MDM2 and CDK4 amplification, but terminology often reflects anatomic behavior. A surgically accessible tumor in an extremity may be called atypical lipomatous tumor because complete removal is usually feasible and distant spread does not occur without dedifferentiation. A similar tumor in the retroperitoneum is commonly called well-differentiated liposarcoma because repeated local recurrence can be difficult to control. The amplification result supports the biologic entity; anatomy and resectability help determine the clinical label and management.
Copy-number thresholds depend on the assay
There is no single universal numeric cutoff that can be copied from one laboratory report to another. FISH may report a gene-to-control ratio or signal pattern, while sequencing assays may estimate copy number from read depth and tumor purity. Chromosomal microarray platforms use yet another analytic framework. The laboratory’s validated threshold, specimen quality, and tumor percentage determine whether a result is called amplified. Borderline or discordant findings should be interpreted by the pathologist with the actual assay criteria rather than by applying an internet cutoff.
A result is most persuasive when copy-number findings, MDM2 status, morphology, and anatomic site agree. When they do not, the discrepancy itself is clinically important and should prompt review rather than an automatic molecular diagnosis. This integrated approach is especially valuable for small biopsies and recurrent retroperitoneal tumors.
References
- Diagnosis and management of dedifferentiated liposarcoma: A multidisciplinary position statement 2024 (Position Statement)
- MDM2-p53 in liposarcoma: The need for targeted therapies with novel mechanisms of action 2024 (Review)
- Histomorphological and molecular characteristics of liposarcoma (Review) 2025 (Review)
- GLI1 Coamplification in Well-Differentiated/Dedifferentiated Liposarcomas: Clinicopathologic and Molecular Analysis of 92 Cases 2024
- Dedifferentiated Liposarcoma: A Comprehensive Historical Review With Proposed Evidence-based Guidelines Regarding a Diagnosis in Need of Further Clarification 2021 (Review)
- Well-differentiated liposarcoma and dedifferentiated liposarcoma: An updated review 2019 (Review)
Disclaimer
CDK4 amplification is a tumor-pathology marker and should be interpreted with MDM2 status, histology, imaging, and tumor location. A positive result does not by itself establish stage, prognosis, or a specific drug choice, and a negative result does not fully exclude liposarcoma. This article is educational and does not replace specialist sarcoma pathology or oncology advice.
